Success Story: NIW Success for Chinese Graduate Student - Approved with Our Tailored Strategy and Premium Processing

 

Client’s Testimonial:

“It’s been a great experience working with your firm, and I really appreciate all the help along the way! The expertise and prompt responses are exceptional, definitely would recommend to anyone who is interested in applying for a green card!”


On April 7th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Graduate Student in the Field of Molecular Biology (Approval Notice).


General Field: Molecular Biology

Position at the Time of Case Filing: Graduate Student

Country of Origin: China

State of Residence at the Time of Filing: Massachusetts

Approval Notice Date: April 7th, 2025

Processing Time: 1 month, 14 days (Premium Processing Requested)


Case Summary:

We are proud to share the successful I-140 NIW approval of an MS holder in molecular and cellular biology whose research is pushing the boundaries of functional genomics and epigenomics to uncover therapeutic strategies for complex diseases such as cancer and tuberculosis. His work focuses on designing next-generation biotechnological interventions for improved patient outcomes.

Currently conducting research in the United States, the client’s proposed endeavor centers on developing advanced tools to study chromatin remodeling and transcriptional regulation, key drivers in diseases linked to gene expression errors. His research directly aligns with U.S. strategic interests in advancing critical and emerging technologies, including synthetic biology, multi-omics, and cancer therapeutics.

To support his petition under the National Interest Waiver (NIW) category, we highlighted:

● 4 peer-reviewed journal articles, including one first-authored paper, published in leading journals;

● 38 citations, with 2 articles ranking among the top 1–10% most cited in molecular biology and genetics for their publication years;

● Research supported by prestigious funding agencies, including the National Institutes of Health, National Cancer Institute, and Howard Hughes Medical Institute.

His work has contributed to understanding chromatin remodeling complexes and RNA polymerase II behavior, laying the foundation for potential therapies targeting gene regulation pathways. Cited by researchers in fields such as cancer biology and transcriptional dynamics, his findings have already informed new directions in chromatin-targeted drug development.

Approved via premium processing after 1 month and 14 days, his NIW case demonstrates the critical value of foundational molecular research to national health, security, and innovation. We congratulate him on this milestone and look forward to his continued impact in his field.